TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02357069
Drug: LBEC0101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept
Study: NCT01941082
Drug: RO6867461
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple ascending dose by intravitreal injection
Study: NCT00069992
Drug: Campath 1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath 1H dosing as per institutional SOPs Day -5 to -2
Study: NCT03166111
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
Study: NCT02753127
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02753127
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05040906
Drug: H02+CHOP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.
Study: NCT05040906
Drug: Rituxan +CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.
Study: NCT03694873
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
Study: NCT00773240
Drug: Grazax
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, 75,000 SQ-T, daily during the trial period
Study: NCT00773240
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo tablet, matching the active treatment, daily during the trial period
Study: NCT00528723
Drug: BDP/salbutamol HFA pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
Study: NCT00528723
Drug: BDP/salbutamol CFC pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
Study: NCT02229942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
Study: NCT02694146
Drug: Hylan G-F 20
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
Study: NCT04338438
Drug: Apatinib Mesylate tablets combined with S-1 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib Mesylate tablets combined with S-1 capsules, p.o.
Study: NCT01549964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching tablets
Study: NCT01861496
Drug: LiPlaCis
Normalized name: Diplacus aurantiacus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: LiPlaCis IV every 3 weeks on day 1, day 8
Study: NCT01498952
Drug: MEDI-573 (1 of 3 doses)
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
Study: NCT00579826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
Study: NCT02060032
Drug: 1.2% simvastatin local drug delivery
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02060032
Drug: Placebo local drug delivery
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00440310
Drug: FOLFOX4 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
Study: NCT00440310
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
Study: NCT01513681
Drug: Lamictal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamictal® 200 mg Tablets
Study: NCT04566653
Drug: Calcium Polystyrene Sulphonate 15g/60 mL water
Approvals — FDA: no, EMA: no, PMDA: no
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study: NCT01352637
Drug: Placebo + Prolonged Imaginal Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
Study: NCT01352637
Drug: Placebo (sugar pill) + Virtual Reality Exposure
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
Study: NCT00624676
Drug: Lipo Hydroxy Acid
Normalized name: alpha hydroxy acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day
Study: NCT00258076
Drug: EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00718328
Drug: Simvastatin 80 mg
Normalized name: simvastatin 80 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
Study: NCT00718328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
Study: NCT03902080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00332709
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg every 6 months
Study: NCT00254410
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
Study: NCT01794091
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 25 mg daily for 6 months
Study: NCT01794091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01244256
Drug: Clotrimazole + Gentamicin + Beclomethasone
Normalized name: betamethasone / clotrimazole / gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Clotrimazole + Gentamicin + Beclomethasone
Study: NCT01244256
Drug: Clotrimazole + Gentamicin
Normalized name: betamethasone / clotrimazole / gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Clotrimazole + Gentamicin
Study: NCT00689247
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution, single dose
Study: NCT01137942
Drug: clarithromycin, metronidazole, proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: appropriate dose of antibiotics and proton pump inhibitor
Study: NCT02661594
Drug: APD421 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of amisulpride
Study: NCT02661594
Drug: APD421 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supra-therapeutic dose of amisulpride
Study: NCT02661594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator to establish baseline for calculating change in QTcF
Study: NCT02276612
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
Study: NCT01398111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pMDI
Study: NCT00005833
Drug: R115777
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg P.O. BID.
Study: NCT03425929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself.
Study: NCT01116258
Drug: AZD5847
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension, 15 days
Study: NCT01116258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension, 15 days
Study: NCT01939587
Drug: PBF-680 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01939587
Drug: PBF-680 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01939587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00885599
Drug: Herbal API
Approvals — FDA: no, EMA: no, PMDA: no
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Study: NCT00885599
Drug: Cepacol
Normalized name: Cepacol
Approvals — FDA: no, EMA: no, PMDA: no
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Study: NCT00885599
Drug: placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Study: NCT01228630
Drug: Cloratadd-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
Study: NCT02696369
Drug: 2% lidocaine HCl with epinephrine 1:200,000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02696369
Drug: 2% lidocaine HCl with epinephrine 1:80,000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02241499
Drug: Oxaliplatin and fluorouracil.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
Study: NCT02357147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression.
Study: NCT01220258
Drug: Azithromycin ophthalmic solution, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
Study: NCT04268420
Drug: FMP013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Falciparum Malaria Protein-13
Study: NCT00368264
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: azathioprine (2 mg/kg) plus four placebo infusions
Study: NCT00066066
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
Study: NCT02245542
Drug: ALNA®OCAS®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02155738
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04918563
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
Study: NCT01851720
Drug: Low dose fentanyl PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01851720
Drug: Standard IV fentanyl bolus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03674060
Drug: SYO-1644
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet
Study: NCT02620904
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006294
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study
Study: NCT01437007
Drug: TKM-080301
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004888
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00705978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03616912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01213979
Drug: 500 mg iron isomaltoside 1000
Normalized name: ferric carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
Study: NCT01213979
Drug: 1000 mg iron isomaltoside 1000
Normalized name: ferric carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
Study: NCT00854945
Drug: ON 01910.Na
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
Study: NCT01687491
Drug: ENOXA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparine 100 UI/Kg subcutaneous injection
Study: NCT01687491
Drug: LOVENOX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparine 100 UI/Kg subcutaneous injection
Study: NCT02032147
Drug: NGF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will be treated with NGF 18u per day im for 60 days
Study: NCT00555984
Drug: Propofol + Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously during surgery for maintenance of General Anesthesia
Study: NCT00555984
Drug: Sevoflurane + Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
Study: NCT02418468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo indacaterol capsules for inhalation daily
Study: NCT03450707
Drug: Thiamine 500 mg IV
Normalized name: thiamine 500 MG
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.
Study: NCT01127750
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00254566
Drug: Azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose 2.0 g oral
Study: NCT03500146
Drug: Anticholinergic
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients prescribed medication for OAB
Study: NCT01110746
Drug: Viaject 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100IU/mL administered subcutaneously
Study: NCT02932904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine Placebo-matching Capsules.
Study: NCT00699010
Drug: Acurox 5/30mg taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: followed by oxycodone 5mg with 48 hour washout
Study: NCT01577758
Drug: MLN0264
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN0264 30-minute infusion on Day 1 of each treatment cycle
Study: NCT03805022
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
Study: NCT03805022
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
Study: NCT03805022
Drug: At the discretion of the investigator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug at the discretion of the investigator.
Study: NCT01966965
Drug: PIOLIN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
Study: NCT03935633
Drug: CN128 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron chelator， oral tablets
Study: NCT03987893
Drug: PEG-3350 with Electolytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental arm will receive 2 doses of PEG3350 spaced over 12 hours after randomization to arm1. PEG as dose of 2litres (1 sachet dissolved in 2L of water) will be administered via a nasogastric tube.
Study: NCT00311896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03437785
Drug: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
Study: NCT03437785
Drug: Placebo of the CKD-495 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of the CKD-495 75mg Tab.
Study: NCT03437785
Drug: Placebo of the CKD-495 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of the CKD-495 150mg Tab.
Study: NCT03437785
Drug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Study: NCT02122536
Drug: Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomized to which side of the face would be treated with Xeomin.
Study: NCT02122536
Drug: Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomized to which side of the upper face would be treated with Botox
Study: NCT01212718
Drug: FUFA
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
Study: NCT02280590
Drug: Rosuvastatin(Cresnon®)
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg
Study: NCT02280590
Drug: Rosuvastatin(Crestor®)
Normalized name: rosuvastatin Oral Tablet [Crestor]
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg
Study: NCT03880903
Drug: hypertonic saline and salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours
Study: NCT03880903
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours
Study: NCT01489072
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
Study: NCT01489072
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
Study: NCT01952756
Drug: Dummy Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet twice per day for 12 weeks
Study: NCT02758392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo on Day 1.
Study: NCT05277844
Drug: TKI
Normalized name: Catkin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKI
Study: NCT02689258
Drug: HTX-011B
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX- 011B (bupivacaine/meloxicam) via injection
Study: NCT02689258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo via injection
Study: NCT02689258
Drug: HTX-011A
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX- 011A (bupivacaine/meloxicam) via injection
Study: NCT02689258
Drug: HTX-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-002 via combination
Study: NCT01050985
Drug: Temsirolimus and capecitabine
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
Study: NCT00696137
Drug: BEMA Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
Study: NCT03823248
Drug: MoLuoDan
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
Study: NCT03823248
Drug: Folic Acid Tablet
Normalized name: Folic Acid Tablets
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.